{"id":"W3175516050","doi":"10.1016/j.eclinm.2021.100940","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial","year":2021,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Erlotinib; Afatinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Hazard ratio; Adverse effect; Surgery; Oncology; Cancer; Epidermal growth factor receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002018093,0.0002502479,0.001308857,0.0001084868,0.00007650943,0.00000289496,0.0001537303,0.00009373109,0.001056385],"category_scores_gemma":[0.0007674337,0.0001186866,0.0007078538,0.001030652,0.0002945987,0.00003265823,0.00004204083,0.0001456455,8.569152e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001325638,"about_ca_system_score_gemma":0.0008627243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007823566,"about_ca_topic_score_gemma":0.0000843644,"domain_scores_codex":[0.9973699,0.0001999892,0.00122191,0.0003707222,0.0006228668,0.0002145839],"domain_scores_gemma":[0.9961414,0.001326282,0.0009414302,0.0009404429,0.0005122777,0.000138194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6663426,0.02416686,0.2892025,0.0004091791,0.008718774,0.00005602892,0.002906529,0.0006110775,0.001078501,0.00004579479,0.0008720262,0.00559019],"study_design_scores_gemma":[0.7898501,0.01408482,0.1575246,0.0001195113,0.02530056,0.00000144517,0.0003274869,0.0004986132,0.01166957,0.000004910543,0.0005026488,0.0001158191],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932497,0.0009376377,0.00002306071,0.0006930996,0.0006794194,0.002280128,0.0003030152,0.000009005172,0.001824894],"genre_scores_gemma":[0.9973897,0.0000388513,0.000188865,0.0001393683,0.0001428148,0.00009034487,0.0003338835,0.00002256268,0.001653602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1316779,"threshold_uncertainty_score":0.9998568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03098304793494916,"score_gpt":0.3744962889247768,"score_spread":0.3435132409898276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}